Antidiabetic treatment for NASH?
Maher
J
J
Liver Center and Department of Medicine, University of California, San Francisco, San Francisco General Hospital, USA.
D000818:Animals; D022762:CCAAT-Enhancer-Binding Proteins / Q000235:genetics / Q000378:metabolism; D002839:Chromans / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000378:metabolism; D005234:Fatty Liver / Q000188:drug therapy* / Q000378:metabolism; D006505:Hepatitis / Q000188:drug therapy* / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007515:Islets of Langerhans / Q000378:metabolism; D020738:Leptin / Q000097:blood; D008099:Liver / Q000378:metabolism; D009765:Obesity; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011924:Rats, Zucker; D051780:Sterol Regulatory Element Binding Protein 1; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D014157:Transcription Factors; D000077288:Troglitazone
D022762:CCAAT-Enhancer-Binding Proteins; D002839:Chromans; D004268:DNA-Binding Proteins; D007004:Hypoglycemic Agents; D020738:Leptin; D012333:RNA, Messenger; C497389:Srebf1 protein, rat; D051780:Sterol Regulatory Element Binding Protein 1; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D000077288:Troglitazone